Clinical Trial Update: ORION-1: Study of AVZO-023 as a Single Agent and in Combination With AVZO-021, and/or Endocrine Therapy in Advanced Solid Tumors [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update for ORION-1 studying AVZO-023 as a single agent and in combination with AVZO-021 and/or endocrine therapy in advanced breast cancer, curre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Breast Cancer Hormone Receptor-positive

Drugs mentioned

• AVZO-021
• AVZO-023

Snippet

Sponsor: Avenzo Therapeutics, Inc. | Conditions: HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer | Phase 1, Phase 2 | Status: RECRUITING